Garde Capital, Inc. Adaptimmune Therapeutics PLC Transaction History
Garde Capital, Inc.
- $1.87 Billion
- Q2 2025
A detailed history of Garde Capital, Inc. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Garde Capital, Inc. holds 750 shares of ADAP stock, worth $247. This represents 0.0% of its overall portfolio holdings.
Number of Shares
750Holding current value
$247% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ADAP
# of Institutions
75Shares Held
114MCall Options Held
77.5KPut Options Held
14.2K-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$9.04 Million0.43% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR23.8MShares$7.84 Million0.16% of portfolio
-
Two Seas Capital LP Rye, NY20.5MShares$6.77 Million0.15% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$5.64 Million0.32% of portfolio
-
Mpm Asset Management LLC Cambridge, MA5.34MShares$1.76 Million1.54% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $53.9M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...